The Irish laboratory Allergan, owner of 'Botox', has reached an agreement to acquire Tobira, a company specialized in the marketing of therapies for the treatment of diabetes, obesity and other metabolic diseases for 1,695 million dollars (1,516 million euros of euros), he reported in a statement.
The terms of the agreement, which must still receive the approval of the regulatory authorities and that both companies expect to close at the end of 2016, contemplate the payment of $ 28.35 in cash per share of Tobira and up to $ 49.84 per share in actionRelative rights if a series of objectives are met.
The transaction includes two programs for the treatment of non -alcoholic steatohepatitis and is a strategic investment to Allergan, which thus reinforces its R&D division in gastroenterology.
"With the growing rates of diabetes, obesity and other metabolic diseases in the US and in developed countries, non -alcoholic steatohepatitis will be one of the following global pathologies that will face society," said the president and advisorby Allergan, Brent Saunders.
On September 14, Allegán announced an agreement for the acquisition of a company specialized in dermatological drugs Vitae Pharmaceuticals for 639 million dollars (568 million euros) in cash.
